VCYT
VCYT
NASDAQ · Biotechnology

Veracyte Inc

$23.69
-28.83 (-54.89%)
Financial Highlights (FY 2026)
Revenue
523.17M
Net Income
67.13M
Gross Margin
70.1%
Profit Margin
12.8%
Rev Growth
+20.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 70.1% 70.1% 67.1% 67.1%
Operating Margin 11.2% 10.1% -0.5% -0.5%
Profit Margin 12.8% 12.2% -0.4% -0.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 523.17M 434.64M 507.99M 466.85M
Gross Profit 366.74M 304.68M 340.77M 313.18M
Operating Income 58.44M 43.69M -2,427,180 -2,364,906
Net Income 67.13M 50.19M -2,027,984 -2,410,114
Gross Margin 70.1% 70.1% 67.1% 67.1%
Operating Margin 11.2% 10.1% -0.5% -0.5%
Profit Margin 12.8% 12.2% -0.4% -0.5%
Rev Growth +20.4% +20.4% +16.6% +7.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 875.10M 761.72M
Total Equity — — 1.67B 1.94B
D/E Ratio — — 0.52 0.39
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 66.45M 52.44M -2,983,128 -2,794,572
Free Cash Flow — — -1,866,923 -2,624,091